PTPRC and neoplasm: Combining anti-PD-L1 antibody with NPTyr-CXCL9 that expressed CXCL9 significantly increased the tumor infiltration of CD3+ T cells (17.2% of CD45+ lymphocytes in NPTyr-CXCL9 & anti-PD-L1 group).